Ekso Bionics Holdings, Inc.

DB:23E2 Stock Report

Market Cap: €14.5m

Ekso Bionics Holdings Valuation

Is 23E2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 23E2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 23E2's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 23E2's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 23E2?

Key metric: As 23E2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 23E2. This is calculated by dividing 23E2's market cap by their current revenue.
What is 23E2's PS Ratio?
PS Ratio0.8x
SalesUS$17.68m
Market CapUS$15.19m

Price to Sales Ratio vs Peers

How does 23E2's PS Ratio compare to its peers?

The above table shows the PS ratio for 23E2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.8x
GME Geratherm Medical
1x1.9%€21.0m
AAQ1 aap Implantate
1.9xn/a€22.4m
AUG Audientes
12.6xn/a€6.9m
PUS PULSION Medical Systems
3.8xn/a€134.4m
23E2 Ekso Bionics Holdings
0.8x23.8%€15.2m

Price-To-Sales vs Peers: 23E2 is good value based on its Price-To-Sales Ratio (0.8x) compared to the peer average (2.2x).


Price to Sales Ratio vs Industry

How does 23E2's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$830.14m
PHH2 Paul Hartmann
0.3xn/aUS$781.42m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
23E2 0.8xIndustry Avg. 3.6xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: 23E2 is good value based on its Price-To-Sales Ratio (0.8x) compared to the European Medical Equipment industry average (3.7x).


Price to Sales Ratio vs Fair Ratio

What is 23E2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

23E2 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.8x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: 23E2 is good value based on its Price-To-Sales Ratio (0.8x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 23E2 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.62
€5.09
+720.4%
63.6%€8.32€1.85n/a2
Nov ’25€0.75
€5.09
+581.8%
63.6%€8.32€1.85n/a2
Oct ’25€0.99
€5.78
+485.1%
60.0%€9.25€2.31n/a2
Sep ’25€0.97
€5.78
+493.6%
60.0%€9.25€2.31n/a2
Aug ’25€1.02
€5.78
+469.6%
60.0%€9.25€2.31n/a2
Jul ’25€0.93
€5.82
+525.9%
60.0%€9.31€2.33n/a2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.


Discover undervalued companies